Phase I Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Solid Tumors
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer; Head and neck cancer; Oesophageal cancer; Penile cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Dragonboat Biopharmaceutical
- 27 Aug 2024 Status changed from not yet recruiting to completed.
- 08 Nov 2019 New trial record